Clinical application of detection of isolated tumor cells with cancer stem-like cells as prognostic tool in colorectal cancer patient

肿瘤干细胞样细胞检测分离肿瘤细胞作为结直肠癌患者预后工具的临床应用

• 批准号: 21591734
• 负责人: IINUMA Hisae
• 金额: $ 2.75万
• 依托单位: Teikyo University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21591734/
• 关键词: 大腸癌; 癌幹細胞; 血中循環癌細胞; 腹腔遊離癌細胞; 予後予測; 遺伝子診断; 転移予測

In this study, we aimed to clarify a clinical significance of circulating tumor cell(CTC) in peripheral blood(PB) and tumor drainage vein blood(TDVB), and isolated tumor cells(ITC) in peritoneal washings of colorectal cancer(CRC) patients. We selected the multiple genetic marker include the cancer associate marker(CEA), epithelial markers(cytokeratin : CK19, CK20), and cancer stem cell-like cell marker(CD133). In this study, overall survival(OS) and disease-free survival(DFS) of Dukes' stage B and C patients who were positive for CEA, CK and/or CD133 in PB or TDVB were significantly worse than those of patients who were negative for these markers. It was demonstrated that multimarker was a significant prognostic factor for OS and DFS in patients with Dukes stage B and C cancer(JCO 2011, Oncol Rep 2012). Furthermore, we examined the prognostic value of ITC in peritoneal washings from CRC patients after curative resection using multiple molecular markers CEA/CK/CD133.In this study, OS and peritoneal recurrence-free survival rates in CEA, CK and/or CD133 mRNA-positive patients were significantly lower than those of marker gene-negative patients. It was demonstrated that CEA, CK and CD133 mRNAs in peritoneal washings were independent prognostic factors for OS and DFS(Oncology 2010).

在这项研究中，我们旨在阐明外周血（PB）和肿瘤排水静脉血液（TDVB）中循环肿瘤细胞（CTC）的临床意义，以及在大肠癌（CRC）患者的腹膜洗涤中分离的肿瘤细胞（ITC）。我们选择了多个遗传标记物包括癌症助理标记（CEA），上皮标记（Cytokeratin：CK19，CK20）和癌症干细胞样细胞标记（CD133）。在这项研究中，在PB或TDVB中对CEA，CK和/或CD133呈阳性的DUKES B和C患者的总生存期（OS）和无病生存率（DFS）明显差于这些标志物阴性的患者。事实证明，在DUKES B和C癌症患者中，多标志物是OS和DFS的重要预后因素（JCO 2011，Oncol Rep 2012）。此外，我们检查了使用多个分子标记物CEA/CK/CD133治疗后CRC患者腹膜洗涤的ITC的预后价值。在这项研究中，OS和CK，CK和/或CD133 MRNA-PORSITIST患者的OS和腹膜复发生存率低于Marker-Gene-Neegenegene-Neegengiate Genegengegatiation。证明腹膜洗涤中的CE，CK和CD133 mRNA是OS和DFS的独立预后因素（Oncology 2010）。

项目成果

Usefulness of the Mononucleotide Marker "BAT-26" for Identification of Microsatellite Instahility in Colorectal Cancers.

单核苷酸标记“BAT-26”用于鉴定结直肠癌中微卫星不稳定性的有用性。

• 发表时间: 2011
• 期刊: Asian Pac J Cancer Prev
• 作者: Watanabe T;Iinuma H;et al.
• 通讯作者: et al.

Predictive value of cancer stem-like cells for peritoneal recurrence of colorectal cancer patient

癌症干细胞样细胞对结直肠癌患者腹膜复发的预测价值

• 发表时间: 2010
• 作者: Tamura J;Iinuma H;et al.
• 通讯作者: et al.

食道癌に対する化学放射線療法と新規ペプチドワクチン併用療法

食管癌放化疗与新型肽疫苗联合治疗

• 发表时间: 2010
• 作者: 飯沼久恵;他
• 通讯作者: 他

「分子標的療法」座長

“分子靶向治疗”主席

• 发表时间: 2009
• 作者: 衣笠哲史;白水和雄;赤木由人;牛島正貴;白土一太郎;石橋生哉;緒方裕;飯沼久恵
• 通讯作者: 飯沼久恵

消化器癌に対する分子生物学の臨床応用

分子生物学在消化道肿瘤中的临床应用

• 发表时间: 2011
• 作者: 飯沼久恵;渡邉聡明;他
• 通讯作者: 他